Dren Bio

United States · Biotech

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

Product

The clinical-stage biotechnology company advances investigational medicines through clinical studies. Its pipeline includes dibotatug and programmes built on a platform designed to engage myeloid cells in clearing disease-related targets.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Private financing$350MJuvia Group — LeadLightspeed — Lead8VC — ParticipantAisling Capital — ParticipantArrowMark Partners — ParticipantBVF Partners — ParticipantCormorant Asset Management — ParticipantGeneral Catalyst — ParticipantHBM Healthcare Investments — ParticipantMirae Asset Capital Life Science — ParticipantMission BioCapital — ParticipantOrbiMed — ParticipantSR One — ParticipantTaiho Ventures — Participant
Sourcesdrenbio.com ↗